Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Journal of Gastroenterology and Hepathology

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MEG.0b013e32835d72cfPMID 23325287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe.

  2012cited by this paper
• Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• An apoptosis panel for nonalcoholic steatohepatitis diagnosis.

  2011cited by this paper
• Genetics of alcoholic and nonalcoholic fatty liver disease.

  2011cited by this paper
• How big a problem is non-alcoholic fatty liver disease?

  2011cited by this paper
• Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations

  2010cited by this paper
• Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

  2010cited by this paper
• Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

  2010cited by this paper
• A position statement on NAFLD/NASH based on the EASL 2009 special conference.

  2010cited by this paper
• Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

  2010cited by this paper
• Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

  2009cited by this paper
• Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.

  2009cited by this paper
• Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

  2009cited by this paper
• Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels

  2009cited by this paper
• Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

  2008cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• Non-alcoholic fatty liver disease: the mist gradually clears.

  2008cited by this paper
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

  2007cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

  2007cited by this paper
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

  2006cited by this paper
• Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

  2006cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C

  2006cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Natural history of NAFLD: remarkably benign in the absence of cirrhosis.

  2005cited by this paper
• Prevalence of and risk factors for fatty liver in a general population of Shanghai, China.

  2005cited by this paper
• The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

  2005cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C

  2003cited by this paper
• Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

  2003cited by this paper
• The prevalence and etiology of elevated aminotransferase levels in the United States

  2003cited by this paper
• Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels

  2002cited by this paper
• Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy

  2000cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• The natural history of nonalcoholic fatty liver: A follow‐up study

  1995cited by this paper
• Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors

  1990cited by this paper
• Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis.

  1988cited by this paper
• Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

  year unknowncited by this paper

• Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis

  2025cites this paper
• Proteomic signatures for fibrosis in MASLD: a biopsy-proven dual-cohort study

  2025cites this paper
• Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK).

  2025cites this paper
• Evaluation of a novel albumin platelet product (APP) fibrosis index and three non-invasive fibrosis indices in metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• UK guideline on the transition and management of childhood liver diseases in adulthood

  2024cites this paper
• Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants

  2024cites this paper
• Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate to severe psoriasis.

  2024cites this paper
• Biochemical and nutritional determinants of non-alcoholic fatty liver disease in Omani adult patients: a case-control study

  2024cites this paper
• Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.

  2024cites this paper
• Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply

  2024cites this paper
• Hepatotoxicity of polymeric proanthocyanidins is caused by translocation of bacterial lipopolysaccharides through impaired gut epithelium.

  2023cites this paper
• Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch

  2023cites this paper
• Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study)

  2023cites this paper
• Differential Effects of COVID-19 Hospitalization on the Trajectory of Liver Disease Progression

  2023cites this paper
• Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome

  2022cites this paper
• Fibroscan Compared to Aspartate Aminotransferase to Platelet Ratio Index (APRI) and Aspartate Aminotransferase to Alanine Aminotransferase Ratio (AST to ALT) in the Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in a Terti

  2022cites this paper
• DMSO_A_358744 1703..1713

  2022cites this paper
• Fibrosis Predictive Score in Caucasian Patients with Metabolic Syndrome

  2022cites this paper
• Impact of non-invasive biomarkers on hepatology practice: Past, present and future.

  2022cites this paper
• Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups

  2022cites this paper
• A sequential approach using the age‐adjusted fibrosis‐4 index and vibration‐controlled transient elastography to detect advanced fibrosis in Korean patients with non‐alcoholic fatty liver disease

  2022cites this paper
• Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• Association of dietary insulinaemic potential and odds of non-alcoholic fatty liver disease among adults: A case-control study.

  2021cites this paper
• Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting

  2021cites this paper
• Laboratory based Non-Invasive Markers are Suboptimal in Detecting Advanced Fibrosis in Patients with Non-Alcoholic Steatohepatitis

  2021cites this paper
• Aspectos relevantes de la enfermedad por hígado graso no alcohólico

  2021cites this paper
• The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus

  2021cites this paper
• Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis

  2021cites this paper
• Update on cardiovascular risk in nonalcoholic fatty liver disease

  2021cites this paper
• Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms

  2021cites this paper
• A Dynamic Aspartate‐to‐Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease

  2021cites this paper
• Non-Alcoholic Fatty Liver Disease, Insulin Resistance, Metabolic Syndrome and their Association with Vascular Risk.

  2021cites this paper
• FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic

  2021cites this paper
• Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient.

  2021cites this paper
• Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease

  2020cites this paper
• Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice.

  2020cites this paper
• Providing Care for Fatty Liver Disease Patients

  2020cites this paper
• Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.

  2020cites this paper
• Usefulness of collagen type IV in the detection of significant liver fibrosis in Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• FIB-4 First in Diagnostic Algorithm of MAFLD at the Era of “Global Metabodemic “

  2020cites this paper
• PAST Score a New Predictor Model for Advanced Fibrosis in a Cohort of Non-alcoholic Fatty Liver Disease

  2020cites this paper
• Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa

  2020cites this paper
• Usefulness of Collagen Type IV (cIV) in The Detection of Significative Fibrosis in Nonalcoholic Fatty Liver Disease

  2020cites this paper
• Clinical and pathophysiological aspects of nonalcoholic fatty liver disease in bariatric surgery

  2019cites this paper
• Understanding the Association of Polycystic Ovary Syndrome and Non-alcoholic Fatty Liver Disease.

  2019cites this paper
• The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider

  2019cites this paper
• Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease

  2019cites this paper
• Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease

  2019influential citation
• Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis

  2019cites this paper
• Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'.

  2019cites this paper
• Risk of liver fibrosis beyond a normal alanine aminotransferase level

  2019cites this paper
• Diagnostic Approach to Nonalcoholic Steatohepatitis

  2018cites this paper
• Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review

  2018cites this paper
• DYNAMICS OF MARKERS OF HEPATIC FIBROSIS ON THERAPY LIRAGLUTIDE AT PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH A METABOLIC SYNDROME

  2018cites this paper
• Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.

  2018cites this paper
• Underlying metabolic processes behind non-alcoholic fatty liver disease in population with metabolic syndrome features: Nutritional status and non-invasive liver tools

  2018cites this paper
• Systematic review and meta‐analysis: non‐invasive detection of non‐alcoholic fatty liver disease related fibrosis in the obese

  2018cites this paper
• Diagnosing liver fibrosis: a narrative review of current literature for dermatologists

  2017cites this paper
• Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.

  2017cites this paper
• Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease

  2017cites this paper
• Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease".

  2017cites this paper
• Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease

  2017cites this paper
• Non-Alcoholic Fatty Liver Disease.

  2017cites this paper
• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

  2016cites this paper
• Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease

  2016cites this paper
• Assessment nonalcoholic fatty liver disease fibrosis score for staging and predicting outcome

  2016cites this paper
• How to best diagnose NAFLD/NASH?

  2016cites this paper
• Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

  2016cites this paper
• Modern view of non-alcoholic fatty liver disease

  2016cites this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

  2016cites this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

  2016cites this paper
• Diagnosis of Non-alcoholic fatty liver disease

  2016cites this paper
• Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease

  2016cites this paper
• Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis.

  2015cites this paper
• Nonalcoholic Fatty Liver Disease

  2015cites this paper
• An overview of the genetics, mechanisms and management of NAFLD and ALD.

  2015cites this paper
• Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship?

  2015cites this paper
• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

  2015cites this paper
• Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

  2015cites this paper
• Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography

  2015cites this paper
• Non-invasive scoring systems for predicting NASH in Japan: evidences from Japan Study Group of NAFLD

  2015cites this paper
• Dietary intake and its relationship with non-alcoholic fatty liver disease (NAFLD)

  2015cites this paper
• Non-alcoholic fatty liver disease: when to intervene and with what.

  2015cites this paper
• Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

  2014cites this paper
• Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients☆

  2014cites this paper
• Non-alcoholic fatty liver disease: a practical approach to treatment

  2014cites this paper
• Republished: Non-alcoholic fatty liver disease: a practical approach to treatment

  2014cites this paper
• Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

  2014cites this paper
• Liver Biopsy at the Time of Bariatric Surgery: A Benefit for Patients and the Medical Community

  2014cites this paper
• Treatment of Non-Alcoholic Fatty Liver Disease

  2014cites this paper
• Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification

  2013cites this paper
• Elevated red cell distribution width is associated with advanced fibrosis in NAFLD

  2013cites this paper
• Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging

  2013cites this paper
• Dietary Quality Indices and Biochemical Parameters Among Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

  2013influential citation
• Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification

  2013cites this paper
• Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.

  2013cites this paper